scott gottlieb, about agency concerns. we also heard tms from patients and other -- testimonies from patients and other groups, groups that supported it and groups that opposed right to try. from them to just recently, our committee engaged in multistakeholder efforts to improve the original right to try bill as passed by the senate. it entailed numerous conversations with patients, with advocates, with the administration, with the authors of the bill and stakeholders on all sides of this complex topics. the food and drug administration was never left out of the discussion. in fact, the agency provided valuable input throughout the process and up until the introduction of h.r. 5247. the aim was to open the door to innovative experimental drugs for terminally ill patients without necessarily compromising the vital work and the mission of the food and drug administration. the current compassionate use program at the food and drug administration does make a

scott gottlieb.d that, a lot of conversations about how health care is changing a lot of pressure to the system, of course from the amazon, jpmorgan, berkshire hathaway merger announced just recently a lot of biotech companies, especially the larger ones, under a lot of pressure. bioge biogen, celgene. industry consolidation, cigna, aetna, cvs we'll talk about the most cutting-edged technologies happening in medicine including gene editing, use of big data and joe is going to cap off our whole day with craig venter, pioneer in genetics. stay tuned to catchall of this back over to you. >> meg, thank you. we are excited about this. >> i'm going to -- i only have a half hour i think with venter, meg, and it's all going to be about whether i can extend my life because human longevity is what -- so we're -- it's probably too late to get totally sequenced. >> gene sequenced? >> before 4:30 yeah, totally sequenced. >> maybe if you drop off a blood sample now, joe, they can do it by 4:30. >> you know what, y

i think scott gottlieb will change this and if we allow drug companies to have innovations that are on a conditional basis of -- hey, he was outcome, no you get this many years to pay for it, that i think will solve those emblems. >> you have spoken about outcome based payments or value-based payments. can you talk about what you are thinking up for what you envisioned if he could waive your magic wand,? i will use my example. but i had a free, specialized treatment, and otter -- autoimmunent treatment for my cancer. it had not been approved by the fda, but the fact is that it will be expensive. but if the sba, and i think it goes back to what you said, they will approve processes rather than drugs, and that will lower the cost tremendously for anyone who ends up with what i am in need this last drug that is a final cure. but you need to approve the processes rather than every drug. each one of them will be different. it will be a different molecules. it will be a different chimeric. so what we have to have is a flexibility. that is why cooperation with the fda, rather than being seen

i want to thank scott gottlieb. scott is working on different things but one of them is called right to try. do you know what right to try is? these are for people who are terminally ill and there are very, very good-looking combinations of things or the pills, medicines, potential cures and they're terminal and they are not going to be living much longer and we don't have the right to give them these experimental drugs or these early stage drugs that really show promise. for whatever reason but they say because they don't want to harm somebody, if you can believe it. they don't want to harm. so people will oftentimes go to foreign lands, foreign countries. they will do anything. they want hope. they want hope. right to try. so we're working with congressman greg walden and numerous other senators and congressmen and i think we're going to have good luck. the democrats have been pushing back on it, but i think many of them are also coming along. it's called right to try. a patient is terminal. there's good progress m

want to thank scott gottlieb. scott is working on different things. one of them is call right to try. you know what right to try is? these are for personal that are terminally ill. there are very, very good looking combinations of things or pills, medicines, potential cures. they're terminal. they're not going to be living much longer. we don't have the right to give them these experimental drugs or these early stage drugs that really show promise for whatever reason. but they say because they don't want to harm somebody. so the people will oftentimes go to foreign lands, foreign countries. they'll do anything. they want hope. they want hope. right to try. so we're working with congressman greg walden and numerous other senators and congressmen. i think we're going to have good luck. the democrats have been pushing back on it. many of them are also coming along. it's called right to try. a patient is terminal. there's good progress made with a certain drug. we're going to make it possible for that patient to get that drug. and maybe it's going to work

and they are forward in the media, scott gottlieb and alex aczar, long-term consumer marketplace and. donald trump said it best, who knew healthcare was so complicated. they are trying to get away with gag pricing, you can't tell people what they cost or bring forth transparency and you can quickly compare prices when shopping for healthcare. and to have that power, and we stabilize the marketplace, we see long-term fixes and have a robust healthcare system. >> one of those things that might be better off. and politicians and people need to be patient a. and it could be great for the american people. jillian: time to check in with todd pirate who is having breakfast with friends live from manchester, iowa. have you started eating yet? >> reporter: i have not. i love to eat, that is a shock. i want to show you something, there is the menu. i love the place you walk in the door and they give you a travel sized cup of coffee. and the issues of the day. it went heavily for pres. obama. then donald trump won by 30 points. "fox and friends" kicks off. you know what's awesome? gig-speed int

scott gottlieb, about agency concerns. we also heard tms from patients and other -- testimonies from patients and other groups, groups that supported it and groups that opposed right to try. from them to just recently, our committee engaged in multistakeholder efforts to improve the original right to try bill as passed by the senate. it entailed numerous conversations with patients, with advocates, with the administration, with the authors of the bill and stakeholders on all sides of this complex topics. the food and drug administration was never left out of the discussion. in fact, the agency provided valuable input throughout the process and up until the introduction of h.r. 5247. the aim was to open the door to innovative experimental drugs for terminally ill patients without necessarily compromising the vital work and the mission of the food and drug administration. the current compassionate use program at the food and drug administration does make a good-faith effort to help patients who do not qualify for clinical tr

i also want to thank scott gottlieb. scott is working on different things, but one of them is called right to try. do you know what right to try is? these are the people that are terminally ill, and there are very, very good-looking combinations of things or pills, medicines, potential cures, and they're terminal. and they're not going to be living much longer. and we don't have the right to give them these experimental drugs or these early-stage drugs that really show promise for whatever reason. but they say because they don't want to harm somebody, if you can believe it. so the people will oftentimes go to foreign lands, foreign countries, they'll do anything. they want hope. they want hope. right to try. so we're working with congressman greg walden and numerous other senators and congressmen. and i think we're going to have good luck. the democrats have been pushing back on it, but i think many of them are also coming along. it's called right to try. a patient is terminal. there's good progress made with a certain dr

and i want to thank scott gottlieb. scott is working on different things. but one of them is called right to try. do you what right to try is? these are the people that are terminally ill and there are very, very good looking combinations of things or pills, medicines, potential cures, and they're terminal. and they're not going to be living much longer. and we don't have the right to give them these experimental drugs or these early-stage drugs that really show promise for whatever reason. but they say because they don't want to harm somebody. if you can believe. it they don't want to harm. so the people will often go to foreign lands, foreign countries and do anything -- they want hope. they want hope. right to try. so we're working with congressman greg walden and numerous other senators and congressman and i think we're going to have good luck. the democrats have been pushing back on it, but i think many of them are also coming along. it is called right to try. a patient is terminal, there is good progress made with a certain drug, we're going to make i

until then when the conference gets going again we'll hear from fda commissioner scott gottlieb who spoke to the group this morning. >> thanks a lot and thanks for the opportunity to be a today and nice introduction. i'm grateful for the chance to build the talk to you all. wanted to talk about what we're going to be doing with respect to nutrition, trying to choose nutrition as as a tool to redue the morbidity and mortality associate with chronic disease going for it and try to lay out my think is going to be forward-looking agenda. a lot of our work today has been spent rightly so trying to implement a lot of the provisions in the loss we inherited i think we'll have a profound public health value looking beyond that i wanted to talk to did david about what ie as our agenda looking out over the next year or two. as we all know more than 630,000 americans every year die from heart disease. it's followed closely by cancer. the second leading cause of death in america with 600,000 americans die annually from cancer. while we have made progress in reducing deaths due to cancer and heart dis

and finally, the honorable scott gottlieb who serves as the commissioner for the u.s. food and drug administration. i want to thank you each for being here. this is a very important topic and we look forward to having this discussion today. are you each aware the committee is holding an investigative hearing and when so doing we have the practice of taking testimony under oath. does anyone have an objection to testifying under oath? seeing none, the chair then advises you that under the rules of the house and the rules of the committee you're entitled to be accompanied by counsel. do any of you desire to be accompanied by counsel for the purposes of today's hearing? seeing none i , if you would ple rise, raise your right hand and i will swear you in. do you swear the testimony you are about to give is the truth, the whole truth, and nothing but the truth? you may be seated. you are now under oath and subject to the penalties set forth in title 18, section 1001 of the united states code and you may now each give a five minute summary of your written statement and we wil

scott. gottlieb. he is a physician, a policy expert, and a public health advocate. previously, he was a resident fellow at the american enterprise institute and a professor at the nyu school of medicine, where he also practiced as a hospitalist. i like to share with you to fax you may not know about him. first, he was born in new jersey. anyone else hear from new jersey? state,sey is the garden which makes him uniquely qualified to oversee the safety of fresh produce. second, he raises chickens in his backyard. that thosending is chickens provide eggs to his family. however, i'm going to warn the commissioner that if he decides one day to slaughter and sell purdueckens, secretary might want to talk to him. the concern was that he would focus only on drug and medical products, and neglect food. these concerns, however, were unfounded. it justice first year, he has shown he is a vigorous supporter implementation, a passionate proponent of the important role ntsition plays and help, committed to improving the effectiveness of food recalls. before handing the mic over,

. >> scott gottlieb the fda commissioner will be with us craig winter will be with us talking about thee we'll see whether there will be healthy returns in the market. phil lebeau will talk about healthy returns at the auto show >> it's a big day. that's cnbc's huge healthcare event in new york city i did not apply early. i did not get a ticket at some point this week i want to see joe kernen get nothing one of those cryogenic thing, where you get into po secoone oe things, negative 200 degrees >> joe doesn't have an ifb, he can't hear this. >> i know that that's why i said it >> oh, maybe we should try that in a segment >> where you go in for 30 seconds, get blasted >> it's supposed to be like after the gym, to deal with inflammation i think that's la it i what it . we'll work on that have many healthy returns today. >> we'll see you on "squawk box. thank you. >>> facebook shares down 1% in the latest trade after a 5% drop yesterday. investors have lost more than 50 billion in market cap on facebook since the data scandal broke. that data breach raising concerns about tech giants prote

scott gottlieb coming up part of the administration, but a welcomed fda commissioner given all the dauntinging in healthcare. he is highly praised by just about everyone always good when we have him on. other than that, we do have obviously tariff talk. we'll talk to former treasury secretary jack liu, see what his thinking is. there's some people that like tariffs. usually from states where they have aluminum or steel >> i told you buffalo would rwi? >> i think you did say the bulls not the bills. >> and you said you and secretary liu's political beliefs align so much, that i think the interview will be -- >> sometimes i just let him go it's funny because even though you have been in an administration and you think you're no longer in it anymore, and you just can talk things over rationally, that doesn't happen a lot of times. they still have an axe to grind. >> do you remember where you were the morning when bear stearns -- i'll say it, failed >> yeah. i was same place i am every morning. >> do you remember how it was hair on fire time at that point. that was the beginning when -- there's

this one will hear from food and drug administration commissioner scott gottlieb and later in the day nutrition experts, agriculture reporters, representatives of farmers and state officials will address the gathering. this is live coverage on c-span2 and it should get underway here in just a minute. [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] [inaudible conversations] >> good morning. i see we have

. >> when you hear tough talk from scott gottlieb or out of hhs among the industry, what do you thinky have in mind? >> we look forward to engaging directly in those conversations. i don't want to interject indirect indirectly if i step back, whether it's federal regulators or state regulators or employers or new joint ventures and amazon, everybody is looking for more value. everybody is looking for more value, more personalization, what works for an individual and more transparency. that's what we want as well. so you'll see continued drive and we do so in partnership with our health care professional partner, we're open architected and don't sell proprietary technology and not an ownership based model. we embrace digital capabilities, 85% of the cigna's business to date in the commercial pace is aso or self-funded it's built on transparency it's built on alignment. i think it's reinforcing that everybody recognizes we're not sustainable today as a society we need to improve health and improve affordability and drive it rapidly. >> as far as you know, have you or other leaders of he

until then when the conference gets going again we'll hear from fda commissioner scott gottlieb who spoke to the group this morning.

scott. gottlieb. he is a physician, a policy

let's bring in the fda commissioner scott gottlieb.to ask you, sir, is the opioid crisis the worst thing you're dealing with? >> i think it's the biggest health crisis facing the agency. this began as a problem with prescription drug. we see people transitions to street drug. most of the new addiction still happening to people who are first exposed to opioids from a lawful prescription. we can try to cut down the new addiction by rationalizing prescribing. we have tools to do that. we've been focused on tphart of the mission. >> dana: president trump said recently and the attorney general talking about suing certain drug companies for problems possibly ones in the past. but is this a productive way to do it if you're also trying to work with though companies to find pharmaceutical alternatives to treat opioids or treat pain? >> well, litigations by the justice department, i think that we've all made mistakes in the past in terms of my agency as well, in terms of our view about the addictive potential of these drugs. i think we go back

break right now, but we've heard this morning from food and drug administration commissioner scott gottlieband coming up later today nutrition experts, agricultural reporters and representatives of farmers and state officials will be addressing the gathering and we'll continue our live coverage after the break here on c-span2. c-span, where history infolds daily. in 1979 c-span was created as a public service by america's cable television companies and today, we continue to bring you unfiltered coverage of congress, the white house, the supreme court, and public policy events in washington d.c. and around the country. c-span is brought to you by your cable or satellite provider. provider. >> up next, a discussion on how states can have an independent, nonpartisan redistricting process. representative rod bloom of iowa and alan lowenthal of california join the common cause for the event. this is juster

scott gottlieb, with other stakeholders to ensure this legislation opens the door to innovative, experimental drugs for these patients without necessarily compromising the vital work and the mission of the food and drug administration. the product of those negotiations is a bill that strikes the proper balance between ensuring patient safety and granting access to these treatments. i also want to mention that the subcommittee of health did have a hearing in this regard, october 3. we heard from the commissioner of the food and drug administration during that hearing. we heard from a number of patient groups and stakeholders who felt that it was in fact in their best interest for us to advance legislation. currently, the food and drug administration conducts an expanded access program aimed at helping patients who do not qualify for clinical trials to gain access to therapies that the agency has yet to approve. while this program makes a good faith effort to help those patients, right to try would create an alternative pathway for those individuals, allowing them to access eligible investigati

coming up, we have the ceo of zscale erzscaler and at the top of the next hour, we'll talk to scott gottliebbout his agency's plan to try to cut nicotine levels in cigarettes alerts -- wouldn't you like one from the market when it might be time to buy or sell? with fidelity's real-time analytics, you'll get clear, actionable alerts about potential investment opportunities in real time. fidelity. open an account today. >>> welcome back cybersecurity provider zscaler will start trading today on the nasdaq the ipo marks the first unicorn in cyberkusecurity firms to go public this year joining us right now is jay chaudhry, ceo and cofounder of zscaler. thank you very much for being here >> thank you >> i realize this is the first cybersecurity company going public this year in a big ipo. i know there are some things different about your company you're a pioneer in cloud security, but explain how. a lot of companies explain they do security over the cloud how is this different? >> i was flying from california to new york earlier this week. half the people were working on the plane. probably conne

what scott gottlieb pointed out is that the strong relationship between pharmaceutical manufacturerss deals to be cast in which there cannot be competition. made.deals cannot be these clearly should be looked at. david: on this point, do you have allies in the pharmaceutical industry itself? i talked to alex gorsky of johnson & johnson and he said helpinger one way of was to have transparency on drugs. the pharmaceutical companies feel hostage to the rebate situation. they are getting blamed because if they took us $500, they are given a rebate down to $250, but the patient is still paying 500 dollars because somebody decides get the $250.nies -- the drug companies get the $250. i am not sure rebate, which anything. we should give the patient the net rise. if it comes out of the from mexico company at $250, the patient should get it for $256. david: thank you so much. that is sen. bill cassidy of louisiana from the capital. coming up in the next hour, chief economist neil a richardson will give us housing numbers. live from new york, this is bloomberg. ♪ national insecurity. the whit

scott gottlieb when he took notifies may 2017 one of the mandate hess received from president trump wasringing down drug prices through accelerating drugs getting to market. we talked about what feedback he's getting from the president. take a listen. >> they've been very productive and he's very well informed about what we're doing and takes an interest in it. just on the whole i've had a lot of support from the white house which has really helped us advance some of our bigger initiatives things around what we're doing on opioids and tobacco where we've gotten a lot of support. >> now one of the things that the fda has been focused on recently is trying to speed biosimilars or generic versions of buy logic drugs to market gottlieb pointed out what he calls market schemes that keep these drugs from getting to market and in effect stocks like abbvie and humira, players competing there, pfizer and j&j and amgen making bye logic generics we talked about plans the fda is laying out along those lines listen to what he said. >> there's no silver bullet here in terms of trying to really make t

secretary azar, scott gottlieb, fda commissioner spoke in favor of either a direct concept or associatedwe think it is an idea whose time has come. neil: very interesting. senator bill cassidy, very good seeing you in the flesh. >> thank you, neil. neil: much success, senator from the beautiful state of louisiana. not so beautiful what is happening to facebook right now or technology stocks in general. technology leading this thing but it is not the only thing. we're on top of that after this. ♪ baby boomers, here's something you should know. there's a serious virus out there that 1 in 30 boomers has, yet most don't even know it. a virus that's been almost forgotten. it's hepatitis c. hep c can hide in the body for years without symptoms. left untreated it can lead to liver damage, even liver cancer. the only way to know if you have hep c is to ask your healthcare provider for the simple blood test. if you have hep c, it can be cured. for us, it's time to get tested. it's the only way to know for sure. for us, it's time to get tested. retail. under pressure like never before. and it's co

covered a a gd bit of this food policy conference including today's comments by fda commissioner scott gottlieb. you can find that on our website at c-span.org. coming up in a bit on c-span2, or, not of the marine corps general robert neller will be sitting down with a journalist who covered the pentagon for a conversation about u.s. national defense. that's coming up at 1:10 p.m. eastern again here on c-span2. tonight it's booktv in primetime on c-span2 starting at eight eastern with a discussion on immigration and race relations from the tenth annual tucson festival of books. former senior editor at foreign affairs will be at the tucson festival of books. a discussion on political candidates and elections. from the savannah book festival. >> for nearly 20 years, in depth on booktv has featured the nation best-known nonfiction writers for life conversations about their books. this year as a special project where featuring best-selling fiction writers for our monthly program "in depth" fiction addiction. join us on sunday at noon eastern with walter mosley, his most recent book is down the rive

scott gottlieb who is commissioner of food and drugs that use fda, and later in the day we'll have the dean of the school of nutrition science and policy at tufts university. as of friday nearly 300 people had registered for the conference. many of you are washington area veterans and many of your you e traveled from across the country or even from abroad. as you can see from the attendee list in your packets, we've got a really diverse group. we are joined by consumer advocates, representatives from food industry and government, academics, nutritionals and dietitian this and graduate of law students, and i'd like, whatever you do, wherever you're from, this coverage is a great opportunity to mingle and network with a diverse group of folks and we really appreciate you joining us here today and hope you enjoy the program. if any of you are on twitter you can follow us at cfafoodpolicy tickets on the program at cfafoodpolicy and hashtag is hashtag cfafpc. we have own national food policy at if you have not downloaded already there are instructions on the table and we also have wi-fi you

scott gottlieb, commissioner of food and drug of the u.s. food and drug administration and later in the day we will have the dean of the school of nutrition science and policy at tufts university. nearly 300 people had registered for the conference. many of your washington area veterans and many of you have traveled across the country, from abroad. as you can see from the attendee list in your packet here, we've got a really diverse group of consumer advocate to representatives from food industry, academics, dietitian has been graduate law students and whatever you do, wherever you are from does not risk the great opportunity with a great group of folks and we appreciate you joining us here today and hope you enjoy the program. if any of you are on twitter, you can follow less at times the fa food policy. i think it on your program and hashtag for the conference is # cfa spc. we also have our own national food policy conference app. if you haven't downloaded it already, there are instructions on the table and we have wi-fi that you can plug

scott gottlieb i will be speaking with dr. craig venter about teleportation. cme group.nks manage interest rate changes and airlines hedge fuel costs. all so they can manage their risks and move forward. it's simply a matter of following the signs. they all lead here. cme group - how the world advances. - anncr: as you grow older, -your brain naturally begins to change which may cause trouble with recall. - learning from him is great... when i can keep up! - anncr: thankfully, prevagen helps your brain and improves memory. - dad's got all the answers. - anncr: prevagen is now the number-one-selling brain health supplement in drug stores nationwide. - she outsmarts me every single time. - checkmate! you wanna play again? - anncr: prevagen. healthier brain. better life. your insurance on time. tap one little bumper, and up go your rates. what good is having insurance if you get punished for using it? news flash: nobody's perfect. for drivers with accident forgiveness, liberty mutual won't raise your rates due to your first accident. switch and you could save $782 on home a

on wednesday we'll be featuring investors, including scott gottlieb >>> when we return, tax day quicklysome bitcoin or any other currency, you might need this. >> if you thought crypto currencies were hard to understand, try paying taxes on them we'll break down what you owe if you bought or sold bitcoin or any other coin when sidewa"squa" returns. i think we should do that meeting tomorrow. well wait. what did you think about her? it's definitely a new idea, but there's no business track record. somethin with new sources of data- so, multiply that by her followers, speaking engagements, work experience... credit history. that more accurately assess a business' chances of success.g this is a good investment. she's a good investment. get ready, because we're helping leading companies see it- and see it through-with digital. >>> looking at futures right now, we have some green, triple digit green. the dow looks like it will open up 432 nasdaq up 151 points, s&p 500 looking to open higher as well, 47 points higher we will have a conversation tomorrow morning to see where things land. in th

scott. s >> >> >> >> >> good morning, everyone. gottlieb. he is a physician, a policy expert, and a public health advocate.